This article first appeared on GuruFocus.
Cathie Wood is sticking to her playbook. In her latest weekly update, ARK Invest leaned further into long-term bets on AI infrastructure, gene editing and autonomous technology, while continuing to cut back exposure to Tesla (NASDAQ:TSLA) and other more mature names.
On the buying side, ARK added to positions in Advanced Micro Devices, Broadcom and Taiwan Semiconductor Manufacturing. The moves underline Wood’s conviction that demand for AI computing and chip infrastructure still has plenty of room to grow, even after a strong run for the sector.
ARK also stayed active in life sciences, but with a clear tilt. The firm added shares of Intellia Therapeutics, 10x Genomics, GeneDx and Personalis, while trimming legacy sequencing and diagnostics names. The message is a familiar one from Wood: shift capital toward what ARK sees as next-generation, editing-first platforms.
Autonomous driving and robotics were another focus. ARK added exposure to robotaxis, autonomous trucking and vehicle intelligence across several of its ETFs, reinforcing its long-term automation thesis.
On the flip side, ARK sold more than 86K shares of Tesla worth over $37 million and trimmed holdings in Illumina, Intuit and other software and life sciences names. ARK is clearly rotating away from established leaders and doubling down on early-stage technologies it believes can define the next decade. Investors will be watching whether these high-conviction bets can pay off in a volatile market.